Domain
Life Sciences & MedTech
Biology, devices, and the habit of being quietly good at both.
From bench to bedside is a cliché until you have to walk it. We introduce the people who have the kit, the trial design, and the patience.
Device translation fails for administrative reasons far more often than scientific ones. The sensing works; the sterilisation route was never considered, the usability study was skipped, the quality management system was started after the first prototype, or nobody established who the notified body would be. None of these are hard problems. All of them are expensive when discovered late.
The clinical partner is therefore not a validation step at the end. A clinician involved early will tell you that the device cannot be cleaned between patients, that the workflow has no free hands at that moment, and that the display is unreadable under theatre lights. Each of those observations, arriving in month three rather than month thirty, is worth more than most funding rounds.
The UK's particular advantage is a single health system with genuine longitudinal data and established research infrastructure. Its particular disadvantage is that procurement is slow, cautious and quite reasonably uninterested in novelty for its own sake. Evidence of outcome and of cost is what moves.
- Diagnostics, devices, and the regulation they deserve
- Translation that does not lose the science
- Partnerships between clinic, campus and company
- Usability work done early, while changes are still cheap
- Health economics a commissioner will actually read
What sits inside
The sub-disciplines people actually search for.
Diagnostics and point-of-care
Assay development, sample handling, and the moment a nurse points out that the lid opens on the wrong side.
Medical devices and instrumentation
Design for sterilisation, biocompatibility, electrical safety, and a risk file that was begun before the second prototype.
Digital health and clinical AI
Decision support with a defined intended use, an honest account of its training population, and a plan for post-market surveillance.
Regulatory and quality
UKCA and CE routes, ISO 13485, clinical evaluation, and the difference between a document set and a quality culture.
Clinical study design
Formative usability through to early feasibility studies, with ethics and governance treated as engineering constraints.
Where the UK stands
Without the boosterism, and without the gloom.
- The NIHR infrastructure — biomedical research centres, clinical research facilities and research networks — is the main route to a first study.
- The MHRA regulates devices; the HRA governs research approvals; NICE and NHS commissioners decide whether anything gets bought.
- The golden triangle dominates headlines, but Manchester, Leeds, Birmingham, Glasgow and Cardiff all carry serious clinical research capacity.
- A single payer means health-economic evidence is not optional. It is the argument.
Work that gets commissioned
The shape of a package in this domain.
- Formative usability studies with eight to twelve clinical users under an approved protocol
- Regulatory gap analysis and a realistic route-to-market opinion
- Bench validation against a recognised standard, with a traceable report
- Early feasibility studies in a clinical research facility
- Health-economic modelling aimed at a commissioner rather than an investor
Where projects come unstuck
Reliably, and usually in week nine.
- Designing a device that cannot be cleaned, discovered after tooling
- Starting the quality management system after the design is frozen
- Confusing a biomarker with a business, and a pilot with adoption
- Assuming ethics approval is a formality with a two-week lead time